首页>
外国专利>
FUSED PROTEIN OR PEPTIDE WITH INCREASED HALF LIFETIME IN VIVO, WHICH IS MAINTAINED DUE TO SLOW RELEASE IN VIVO, AND METHOD FOR INCREASING HALF LIFETIME IN VIVO USING IT
FUSED PROTEIN OR PEPTIDE WITH INCREASED HALF LIFETIME IN VIVO, WHICH IS MAINTAINED DUE TO SLOW RELEASE IN VIVO, AND METHOD FOR INCREASING HALF LIFETIME IN VIVO USING IT
FIELD: biotechnologies.;SUBSTANCE: physiologically active protein or polypeptide are fused with version of alpha-1-antitrypsin, which has at least one mutated aminoacid residue. Mutations are performed in the following positions: asparagine residue instead of proline residue in position 357; or asparagine residue instead of proline residue in position 357 and threonine residue instead of serine in position 359; or asparagine residue instead of proline residue in position 357 and serine residue instead of cysteine in position 232; or asparagine residue instead of proline residue in position 357, threonine residue instead of serine in position 359 and serine residue instead of cysteine in position 232.;EFFECT: invention allows increasing half lifetime of physiologically active protein or polypeptide in vivo by maintaining its stable circulation in blood.;7 cl, 13 dwg, 7 ex
展开▼
机译：领域：生物技术。物质：将具有生理活性的蛋白质或多肽与具有至少一个突变氨基酸残基的α-1-抗胰蛋白酶融合。在以下位置进行突变：位置357的天冬酰胺残基而不是脯氨酸残基; 357位是天冬酰胺残基而不是脯氨酸残基，359位是苏氨酸残基而不是丝氨酸残基;或在357位用天冬酰胺残基代替脯氨酸，在232位用丝氨酸残基代替半胱氨酸;或或在357位上用天冬酰胺残基代替脯氨酸，在359位上用苏氨酸残基代替丝氨酸，在232位上用丝氨酸残基代替半胱氨酸。血液中; 7 cl，13 dwg，7 ex
展开▼
